

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **PROFIT ALERT – REDUCTION IN LOSS**

This announcement is made by Tianda Pharmaceuticals Limited (the “Company”, and together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As stated in the announcement of the Company dated 25 November 2022, the financial year end date of the Company has been changed from 31 March to 31 December. In light of this change, the consolidated financial statements for the current interim period cover the six-month period from 1 January 2023 to 30 June 2023 (the “Current Interim Period”) and the comparative figures cover the six-month period from 1 April 2022 to 30 September 2022 (the “Previous Interim Period”).

The board of directors of the Company wishes to inform the shareholders of the Company and potential investors that based on the preliminary assessments on the Group’s unaudited consolidated management accounts for the Current Interim Period, due to an increase in both the revenue and gross profit of the Group by over 20% compared with the Previous Interim Period, it is expected the loss for the Current Interim Period would be reduced by over 70% from HK\$19.1 million in the Previous Interim Period. Excluding R&D expenses, the Group is expected to turnaround from a loss of HK\$7.1 million in the Previous Interim Period to a profit in the Current Interim Period.

The Company is finalising the consolidated interim results of the Group for the Current Interim Period. Hence, the information disclosed in this announcement only represents a preliminary assessment by the Board and the management of the Group based on the information currently available to the Board. This preliminary assessment is not based on any financial figures and/or information which have been audited, verified or reviewed by the Company’s auditor or audit committee. As such, the final results for the Current Interim Period may be different from what is disclosed in this announcement.

The Board expects that the announcement of the interim results of the Group for the Current Interim Period will be published on 28 August 2023 in compliance with the requirements under the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 23 August 2023

*As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. SHEN Bo and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.*